// App-Quantinova.ai

P571 : Vedolizumab (VDZ) real-world outcomes in ulcerative colitis (UC)

Researchers

Presenter

  • S S R Pulusu

Principal Investigators

  • K Krishnaprasad

  • D Cheng

  • T Mogilevski

  • E Flanagan

  • C Keung

  • R Prosser

  • E Sawyer

  • Q -U -A Rizvi

  • H Su

  • W -K Leung

  • A Edmundson

  • S Cooke

  • G Mahy

  • L Thin

  • G Radford-Smith

  • M Sparrow

  • J M Andrews

  • S Connor

  • P Bampton

  • S Ghaly

  • D Van Langenberg

  • S Bell

  • P De Cruz

  • J Begun

  • S Travis

  • I Lawrance

Medical Centers

  • St John of God, Subiaco, IBD Center, Perth, Australia

  • Oxford University Hospital, Oxford,

  • QIMR Berghofer Medical Research Institute, Brisbane, Sydney, Australia

  • Mater Hospital, Brisbane, Australia

  • Austin Health, Melbourne, Australia

  • St Vincent's Hospital, Melbourne, Australia

  • Austin Health, Melbourne, Australia

  • St Vincents Hospital, Sydney, Australia

  • Flinders University Medical Centre, Adelaide, Australia

  • Liverpool Hospital, Sydney, Australia

  • Royal Adelaide Hospital and University of Adelaide, Adelaide, Australia

  • The Alfred Hospital, Melbourne, Australia

  • The Chinese University of Hong Kong, Hong Kong, Hong Kong

  • The Townsville Hospital, Townsville, Australia

  • Fiona Stanley Hospital, Perth, Australia

  • Flinders University Medical Centre, Adelaide, Australia

  • The Chinese University of Hong Kong, Hong Kong, Hong Kong

Locations

  • Australia

  • United Kingdom

  • Hong Kong

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Entyvio

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved